- Home
- Publications
- Publication Search
- Publication Details
Title
Aggressive prolactinomas: how to manage?
Authors
Keywords
-
Journal
Pituitary
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-10-16
DOI
10.1007/s11102-019-01000-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas
- (2019) Dongyun Zhang et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Clinical, pathological and molecular factors of aggressiveness in lactotroph tumours
- (2019) Jacqueline Trouillas et al. NEUROENDOCRINOLOGY
- Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience
- (2019) G Giuffrida et al. Endocrine Connections
- Confirmation of a new therapeutic option for aggressive or dopamine agonist-resistant prolactin pituitary neuroendocrine tumors
- (2019) Gerald Raverot et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma
- (2019) Eva C Coopmans et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- 65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update
- (2018) Luis V Syro et al. ENDOCRINE-RELATED CANCER
- Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016
- (2018) Ann McCormack et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy
- (2018) Peng-fei Wang et al. JOURNAL OF NEURO-ONCOLOGY
- Pasireotide: A potential therapeutic alternative for resistant prolactinoma
- (2018) Hélène Lasolle et al. ANNALES D ENDOCRINOLOGIE
- Marked response of a hypermutated adrenocorticotropic hormone-secreting pituitary carcinoma to ipilimumab and nivolumab
- (2018) Andrew L Lin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Management of dopamine agonist-resistant prolactinoma
- (2018) Dominique Maiter NEUROENDOCRINOLOGY
- Sex-Related Differences in Lactotroph Tumor Aggressiveness Are Associated With a Specific Gene-Expression Signature and Genome Instability
- (2018) Anne Wierinckx et al. Frontiers in Endocrinology
- Long-Term Survival After Transformation of an Adrenocorticotropic Hormone–Secreting Pituitary Macroadenoma to a Silent Corticotroph Pituitary Carcinoma
- (2018) Lauren E. Rotman et al. World Neurosurgery
- Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas
- (2017) Hélène Lasolle et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas
- (2017) Gerald Raverot et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Complementary actions of dopamine D2 receptor agonist and anti-vegf therapy on tumoral vessel normalization in a transgenic mouse model
- (2017) Norbert Chauvet et al. INTERNATIONAL JOURNAL OF CANCER
- Aggressive Pituitary Adenomas: The Dark Side of the Moon
- (2017) Stefano M. Priola et al. World Neurosurgery
- Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors
- (2016) Marie Chanal et al. MOLECULAR CANCER THERAPEUTICS
- Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas
- (2016) Ilan Shimon et al. Pituitary
- Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
- (2016) Yu Mei et al. Oncotarget
- Improvement in Diagnosis of Metastatic Pituitary Carcinoma by 68Ga DOTATATE PET/CT
- (2015) Jianqi Xiao et al. CLINICAL NUCLEAR MEDICINE
- Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth
- (2015) E. Delgrange et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide
- (2015) Daniel Bengtsson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Macroprolactinomas in Children and Adolescents: Factors Associated With the Response to Treatment in 77 Patients
- (2015) Sylvie Salenave et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Gamma Knife radiosurgery for medically and surgically refractory prolactinomas: long-term results
- (2015) Or Cohen-Inbar et al. Pituitary
- The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy
- (2014) Youwei Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- DNA Mismatch Repair Protein (MSH6) Correlated With the Responses of Atypical Pituitary Adenomas and Pituitary Carcinomas to Temozolomide: The National Cooperative Study by the Japan Society for Hypothalamic and Pituitary Tumors
- (2013) Toshio Hirohata et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Management of medically refractory prolactinoma
- (2013) Mark E. Molitch JOURNAL OF NEURO-ONCOLOGY
- Temozolomide-Related Hematologic Toxicity
- (2013) Claudia Scaringi et al. ONKOLOGIE
- Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation
- (2013) Jillian Maclean et al. Pituitary
- Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment
- (2012) Melanie Philippon et al. ANNALES D ENDOCRINOLOGIE
- Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients
- (2012) Laurent Vroonen et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients
- (2012) V. Primeau et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
- (2011) Shlomo Melmed et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- New targeted therapies in pituitary carcinoma resistant to temozolomide
- (2011) Emmanuel Jouanneau et al. Pituitary
- Anti-VEGF therapy in pituitary carcinoma
- (2011) Leon D. Ortiz et al. Pituitary
- Prognostic Factors in Prolactin Pituitary Tumors: Clinical, Histological, and Molecular Data from a Series of 94 Patients with a Long Postoperative Follow-Up
- (2010) Gérald Raverot et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- HER2/ErbB2 Receptor Signaling in Rat and Human Prolactinoma Cells: Strategy for Targeted Prolactinoma Therapy
- (2010) Hidenori Fukuoka et al. MOLECULAR ENDOCRINOLOGY
- Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients
- (2009) Etienne Delgrange et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma
- (2009) Alessandra Fusco et al. Pituitary
- Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas
- (2008) Alessandra Fusco et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started